following a resubmission assessed under the end of life and orphan medicine process:
encorafenib (Braftovi®) is accepted for use within NHSScotland
Indication under review: In combination with binimetinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
Progression-free survival was significantly longer in the encorafenib plus binimetinib group compared with BRAF inhibitor monotherapy in a phase III study of patients with unresectable or metastatic BRAF V600 melanoma.
This advice applies only in the context of approved NHSScotland Patient Access Scheme (PAS) arrangements delivering the cost-effectiveness results upon which the decision was based, or PAS/ list prices that are equivalent or lower.
This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting.
- Medicine name:
- encorafenib (Braftovi)
- SMC ID:
In combination with binimetinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
- Pharmaceutical company
- Pierre Fabre Ltd
- Submission type
- Date advice published
- 10 February 2020